POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)
A Multicenter, Randomized, Controlled, Double-Blind, Double-Dummy, Two-Arm Study of Posaconazole vs Fluconazole in the Treatment of Coccidioidomycosis
研究概览
研究类型
注册 (实际的)
阶段
- 第三阶段
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Thirteen years of age or older, 34 kg (75 lb) or more, either sex, and any race;
- Coccidioides immitis (C. immitis) or Coccidioides posadasii (C. posadasii) identified by culture or microscopic examination from skeletal disease, chronic active pulmonary disease, or soft tissue disease;
- Coccidioidomycosis score of >=6;
- Clinical laboratory safety tests within normal limits or clinically acceptable to the sponsor;
- Free of any clinically significant disease that would interfere with study evaluations;
- Willing to give written informed consent and able to adhere to study medication dose, mandatory procedures (including human immunodeficiency virus (HIV) testing), and visit schedules;
- Able to swallow food or a nutritional supplement;
- Use of a medically accepted method of contraception;
- Negative serum pregnancy test at Screening and negative urine pregnancy test at Randomization;
- Women of childbearing potential not currently sexually active must agree to use a medically accepted method of contraception should they become sexually active while participating in the study.
Exclusion Criteria:
- Key Exclusion Criteria
Excluded Medications at Enrollment
- Medications that are known to interact with POS or FLU and that may lead to serious or life threatening side effects within 7 days prior to initiating study drug;
- Medications known to lower the serum concentration/efficacy of azole antifungals within 7 days prior to study drug start;
- Prior investigational drug use or biologic product administration within 30 days before study drug start;
- Prior antifungal treatment for the current episode of infection with a total cumulative dose of >=8 g of any azole, >=4 mg/kg of amphotericin B deoxycholate, or >=20 mg/kg of lipid amphotericin B;
Antiretrovirals that are substrates of CYP3A4 administered to HIV-positive subjects, as it is not currently known how POS or FLU may affect such drugs or the potential to cause adverse reactions.
- Excluded Concomitant Conditions
- Immediately life-threatening coccidioidomycosis;
- Confirmed or suspected meningeal coccidioidomycosis;
- Pulmonary coccidioidomycosis in HIV-negative subjects for less than 3 months;
- Any condition requiring use of prohibited drugs;
Cluster of Differentiation 4 (CD4) count of <200 cells/mm3 or any auto-immune deficiency syndrome (AIDS)-defining illness in HIV-positive subjects in the prior 30 days.
- Excluded Baseline Laboratory Studies
- Moderate or severe liver dysfunction (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 times upper limit of normal (ULN)) or a total bilirubin level or direct bilirubin > 3 times ULN plus ALT or AST >2 times ULN (Hy's Rule);
- Moderate or severe renal dysfunction (creatinine clearance (CrCl) <20 mL/min) or dialysis required or expected to be required within the study period;
Electrocardiogram (ECG) with a prolonged QTc interval by manual reading: QTc >450 msec for males and QTc >470 msec for females.
- General Exclusion Criteria
- Prior enrollment in this study or other POS studies;
- Failed treatment with FLU or POS at any time in the past;
- History of hypersensitivity or idiosyncratic reactions to azole drug therapy;
- Women who are pregnant, intend to become pregnant, or are breast-feeding;
- Situation or condition that may interfere with optimal participation in the study;
Part of the staff personnel directly involved with this study;
- Family member of the investigational study staff.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Posaconazole
Eligible subjects will be stratified at Baseline by disease site (skeletal, lung, or soft tissue) and by immune status (immunocompromised or non-immunocompromised) and will then be randomly assigned to receive Posaconazole 400 mg orally (PO) (oral suspension 40 mg/mL) administered twice daily with meals or oral nutritional supplements for 12 months.
|
Posaconazole 400 mg orally (PO) (oral suspension 40 mg/mL) administered twice daily with meals or oral nutritional supplements for 12 months
|
有源比较器:Fluconazole
Eligible subjects will be stratified at Baseline by disease site (skeletal, lung, or soft tissue) and by immune status (immunocompromised or non-immunocompromised) and will then be randomly assigned to receive Fluconazole 400 mg PO (given as two 200-mg oral encapsulated tablets) administered once daily for 12 months.
Fluconazole treatment or placebo only occurred during Period A.
|
Fluconazole 400 mg PO (given as two 200-mg oral encapsulated tablets) administered once daily for 12 months
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Number of Participants With Treatment-related Treatment-emergent Adverse Events (TRAEs) That Occurred With Posaconazole (POS) or Fluconazole (FLU) in Period A
大体时间:12 months
|
Treatment-emergent adverse events are defined as new events that occur following subject entry into the study or events that worsen following study entry state. Treatment-related adverse events are defined as new events that occur following subject entry into the study or events that worsen following study entry state and are judged by the investigator to be possibly, probably or definitely related to study medication. |
12 months
|
Number of Participants With Treatment-related Treatment-emergent Adverse Events (TRAEs) That Occurred With Posaconazole (POS) in Period B
大体时间:12 months
|
Treatment-emergent adverse events are defined as new events that occur following subject entry into the study or events that worsen following study entry state. Treatment-related adverse events are defined as new events that occur following subject entry into the study or events that worsen following study entry state and are judged by the investigator to be possibly, probably or definitely related to study medication. |
12 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Number of Participants With Treatment-emergent Adverse Events (TEAEs)That Occurred With POS or FLU in Period A
大体时间:12 months
|
Treatment-emergent adverse events are defined as new events that occur following subject entry into the study or events that worsen following study entry state.
|
12 months
|
Number of Participants With Treatment-emergent Adverse Events (TEAEs) That Occurred With POS in Period B
大体时间:12 months
|
Treatment-emergent adverse events are defined as new events that occur following subject entry into the study or events that worsen following study entry state.
|
12 months
|
Number of Participants With Laboratory Test Abnormalities (at Least a 1 Grade Shift From Baseline) That Occurred With POS or FLU in Period A
大体时间:12 months
|
Severity grading was based on Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.
This is a descriptive terminology which can be utilized for Adverse Event (AE) reporting.
A grading (severity) scale is provided for each AE term.
CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE; Grade 2 Moderate AE; Grade 3 Severe AE; Grade 4 Life-threatening or disabling AE; Grade 5 Death related to AE.
|
12 months
|
Number of Participants With Laboratory Abnormalities (at Least a 1 Grade Shift From Baseline) That Occurred With POS in Period B
大体时间:12 months
|
Severity grading was based on Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.
This is a descriptive terminology which can be utilized for Adverse Event (AE) reporting.
A grading (severity) scale is provided for each AE term.
CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE; Grade 2 Moderate AE; Grade 3 Severe AE; Grade 4 Life-threatening or disabling AE; Grade 5 Death related to AE.
|
12 months
|
Number of Participant Discontinuations Due to Adverse Events and/or Laboratory Evaluations of Safety in Period A
大体时间:12 months
|
12 months
|
|
Number of Participant Discontinuations Due to Adverse Events and/or Laboratory Evaluations of Safety in Period B
大体时间:12 months
|
12 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- P04558
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.